1 Jul 2016

Panacea launches diabetes drug ‘Tenepan’ in India

Posted Byadmin

Comments0

TagsDPP4 Inhibitor, Panacea Biotec, Teneligliptin, Tenepan

Panacea Biotec has launched diabetes drug ‘Tenepan’, used for treating Type 2 Diabetes Mellitus, in India.

Tenapan aims to improve the accessibility of diabetes treatment at an affordable cost as part of the company’s commitment to the Make in India’ campaign.

Molecule: Teneligliptin
Class: DPP4 Inhibitor

Why this launch?

Panacea Biotech is having strong presence in Diabetes market through Diacar Alpha Business Team. Panacea Biotech is holding leadership position in Glicazide market with its brand Glizid-M.
Teneligliptin will further strengthen the position of Panacea in diabetes market segment.
Teneligliptin works in synergy with the sulphonylureas to manage the patients with uncontrolled on Metformin therapy and / or a sulphonylurea therapy.